Who
Ian T. Clark
Director
Company insider
Files Form 4 as: Director, Guardant Health; Director, Olema Pharmaceuticals; Director, Corvus Pharmaceuticals; Director, BioMarin Pharmaceutical; Director, Kyverna Therapeutics; Director, GoodRx Holdings; Director, Tectonic Therapeutic; Director, Agios Pharmaceuticals.
In numbers
- Trades disclosed
- 595
- Buys
- 1
- Sells
- 58
- Bought
- $54K
- Sold
- $43.9M
- Companies
- 13
- Companies where not an officer
- 12
- First trade
- 20 Sep 2006
- Last trade
- 4 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | $205K2,255 at $91.11 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | $346K6,833 at $50.57 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1.4M9,088 at $158.98 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —2,255 at $0.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —6,833 at $0.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $809K5,092 at $158.80 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —2,255 at $0.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —6,833 at $0.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | $205K2,255 at $91.11 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | $346K6,833 at $50.57 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1.4M9,088 at $158.98 | filing |
| 4 Aug 2026filed 5 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $809K5,092 at $158.80 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —5,092 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —5,092 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —5,092 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —5,092 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?GH · insidermonkey.com · 20 Oct 2026Guardant Health (NASDAQ:GH) Director Sells $19,242.08 in StockGH · themarketsdaily.com · 19 Oct 2026Guardant Health (NASDAQ:GH) Stock Price Down 6.4% – Time to Sell?GH · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Ian T. Clark; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.